Sarda Proteins Ratios

Sarda Proteins Ltd Ratios

The Sarda Proteins Ltd Ratios page provides a complete fundamental analysis of Sarda Proteins Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Sarda Proteins Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Sarda Proteins Ltd (NSE: , BSE: 519242) is currently trading at ₹84.48, with a market capitalization of ₹145.8M. As a major player in the Process industries sector and Agricultural commodities/Milling industry, Sarda Proteins Ltd remains a key stock for fundamental analysis using Sarda Proteins Ltd Ratios.

Sarda Proteins Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Sarda Proteins Ltd P/E ratio currently stands at 4210, making it one of the most tracked metrics in Sarda Proteins Ltd Ratios.

Historically, the Sarda Proteins Ltd P/E ratio has shown strong fluctuations:

• 2024: 4210
• 2023: 478.13
• 2022: 0
• 2021: 20.94
• 2020: 0

The rising Sarda Proteins Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Sarda Proteins Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 9.05.

Historical P/B trend:

• 2024: 9.05
• 2023: 3.91
• 2022: 4.24
• 2021: 2.70

Sarda Proteins Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Sarda Proteins Ltd P/S ratio currently stands at 0.89, an important part of Sarda Proteins Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.89
• 2023: 7.16
• 2022: 1.72
• 2021: 0.60

A stable or declining Sarda Proteins Ltd P/S ratio indicates cautious market sentiment.

Sarda Proteins Ltd Price to Cash Flow Ratio (P/CF)

The Sarda Proteins Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Sarda Proteins Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 33.97
• 2020: 57.22

The declining Sarda Proteins Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Sarda Proteins Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Sarda Proteins Ltd EV currently stands at ₹214.97M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 214.97M
• 2023: 91.65M
• 2022: 97.84M
• 2021: 61.12M

Sarda Proteins Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Sarda Proteins Ltd EV/EBITDA ratio is currently 1100, a key metric in Sarda Proteins Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 1100
• 2023: 0
• 2022: 0
• 2021: 22.59

Higher Sarda Proteins Ltd EV/EBITDA suggests premium valuation.

Sarda Proteins Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Sarda Proteins Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Sarda Proteins Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Sarda Proteins Ltd ROE currently stands at 0.21%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 0.21
• 2023: 0.82
• 2022: -1.39
• 2021: 13.77

Declining ROE indicates pressure on profitability.

Sarda Proteins Ltd Ratios Analysis Summary

The Sarda Proteins Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Sarda Proteins Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Sarda Proteins Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.